Untangling, designing
and interpreting to ensure your products succeed

Headed by a consultant biostatistician with over 25 years of experience in the pharmaceutical industry, Stone Biostatistics provides innovative solutions in optimising drug development programmes specialising in oncology.

​Andrew Stone is a former head of the Biometrics oncology TA at AstraZeneca and has significant regulatory experience, leading biostatistics teams to the submission or approval of six oncology products

Find out more
Find out more
Find out more
Find out more

© 2016 Stone Biostatistics

  • LinkedIn